Literature DB >> 27306623

Biologics in Pediatric Rheumatology: Quo Vadis?

Yonit Sterba1, Norman Ilowite2.   

Abstract

The past two decades have brought immense satisfaction to pediatric rheumatologists and families of children with rheumatologic diseases. We have been able to better classify, recognize, and diagnose rheumatologic diseases, but most importantly, the discovery of biologic therapies and their efficacy and relative safety in treating multiple rheumatologic conditions, improving quality of life for the patients we care for. We will review the advances of the past two decades and discuss potential areas for new discoveries.

Entities:  

Keywords:  Abatacept; IL-1 inhibitors; IL-6 inhibitors; Juvenile idiopathic arthritis (JIA); Rituximab; TNF inhibitors; Tofacitinib

Mesh：

Substances：

Year:  2016        PMID： 27306623     DOI： 10.1007/s11926-016-0593-9

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.686


  38 in total

1.  Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis.

Authors:  Maja Bulatovic; Marloes W Heijstek; E H Pieter Van Dijkhuizen; Nico M Wulffraat; Saskia M F Pluijm; Robert de Jonge
Journal:  Ann Rheum Dis       Date:  2012-04-03       Impact factor: 19.103

2.  Malignancies in juvenile idiopathic arthritis: a preliminary report.

Authors:  Sasha Bernatsky; Alan M Rosenberg; Kiem G Oen; Ciaran M Duffy; Rosalind Ramsey-Goldman; Jeremy Labrecque; Yvan St Pierre; Ann E Clarke
Journal:  J Rheumatol       Date:  2011-01-15       Impact factor: 4.666

3.  Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).

Authors:  Denis Poddubnyy; Kay-Geert A Hermann; Johanna Callhoff; Joachim Listing; Joachim Sieper
Journal:  Ann Rheum Dis       Date:  2014-01-03       Impact factor: 19.103

4.  Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.

Authors:  Dirk Foell; Nico Wulffraat; Lucy R Wedderburn; Helmut Wittkowski; Michael Frosch; Joachim Gerss; Valda Stanevicha; Dimitrina Mihaylova; Virginia Ferriani; Florence Kanakoudi Tsakalidou; Ivan Foeldvari; Ruben Cuttica; Benito Gonzalez; Angelo Ravelli; Raju Khubchandani; Sheila Oliveira; Wineke Armbrust; Stella Garay; Jelena Vojinovic; Ximena Norambuena; María Luz Gamir; Julia García-Consuegra; Loredana Lepore; Gordana Susic; Fabrizia Corona; Pavla Dolezalova; Angela Pistorio; Alberto Martini; Nicolino Ruperto; Johannes Roth
Journal:  JAMA       Date:  2010-04-07       Impact factor: 56.272

5.  Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.

Authors:  Fabrizio De Benedetti; Hermine I Brunner; Nicolino Ruperto; Andrew Kenwright; Stephen Wright; Inmaculada Calvo; Ruben Cuttica; Angelo Ravelli; Rayfel Schneider; Patricia Woo; Carine Wouters; Ricardo Xavier; Lawrence Zemel; Eileen Baildam; Ruben Burgos-Vargas; Pavla Dolezalova; Stella M Garay; Rosa Merino; Rik Joos; Alexei Grom; Nico Wulffraat; Zbigniew Zuber; Francesco Zulian; Daniel Lovell; Alberto Martini
Journal:  N Engl J Med       Date:  2012-12-20       Impact factor: 91.245

6.  Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes.

Authors:  H Mangge; H Kenzian; S Gallistl; G Neuwirth; P Liebmann; W Kaulfersch; F Beaufort; W Muntean; K Schauenstein
Journal:  Arthritis Rheum       Date:  1995-02

7.  Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

Authors:  Iain B McInnes; Arthur Kavanaugh; Alice B Gottlieb; Lluís Puig; Proton Rahman; Christopher Ritchlin; Carrie Brodmerkel; Shu Li; Yuhua Wang; Alan M Mendelsohn; Mittie K Doyle
Journal:  Lancet       Date:  2013-06-13       Impact factor: 79.321

8.  Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.

Authors:  Marieke H Otten; Janneke Anink; Femke H M Prince; Marinka Twilt; S J Vastert; Rebecca ten Cate; Esther P A H Hoppenreijs; Wineke Armbrust; Simone L Gorter; Philomine A van Pelt; Sylvia S M Kamphuis; Koert M Dolman; Joost F Swart; J Merlijn van den Berg; Yvonne Koopman-Keemink; Marion A J van Rossum; Nico M Wulffraat; Lisette W A van Suijlekom-Smit
Journal:  Ann Rheum Dis       Date:  2014-03-18       Impact factor: 19.103

9.  Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade.

Authors:  Virginia Pascual; Florence Allantaz; Edsel Arce; Marilynn Punaro; Jacques Banchereau
Journal:  J Exp Med       Date:  2005-04-25       Impact factor: 14.307

10.  Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.

Authors:  Christopher Ritchlin; Proton Rahman; Arthur Kavanaugh; Iain B McInnes; Lluis Puig; Shu Li; Yuhua Wang; Yaung-Kaung Shen; Mittie K Doyle; Alan M Mendelsohn; Alice B Gottlieb
Journal:  Ann Rheum Dis       Date:  2014-01-30       Impact factor: 19.103
View more
  6 in total

Review 1.  Pediatric macrophage activation syndrome, recognizing the tip of the Iceberg.

Authors:  Courtney Crayne; Randy Q Cron
Journal:  Eur J Rheumatol       Date:  2019-12-03

2.  Value of Literature Review to Inform Development and Use of Biologics in Juvenile Idiopathic Arthritis.

Authors:  Klervi Golhen; Carolyn Winskill; Cynthia Yeh; Nancy Zhang; Tatjana Welzel; Marc Pfister
Journal:  Front Pediatr       Date:  2022-06-21       Impact factor: 3.569

Review 3.  The Immunology of Macrophage Activation Syndrome.

Authors:  Courtney B Crayne; Sabrin Albeituni; Kim E Nichols; Randy Q Cron
Journal:  Front Immunol       Date:  2019-02-01       Impact factor: 7.561

Review 4.  The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children: a meta-analysis.

Authors:  Arnold Nagy; Péter Mátrai; Péter Hegyi; Hussain Alizadeh; Judit Bajor; László Czopf; Zoltán Gyöngyi; Zoltán Kiss; Katalin Márta; Mária Simon; Ágnes Lilla Szilágyi; Gábor Veres; Bernadett Mosdósi
Journal:  Pediatr Rheumatol Online J       Date:  2019-01-18       Impact factor: 3.054

Review 5.  Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology - what we know and what we do not know from randomized controlled trials.

Authors:  Tatjana Welzel; Carolyn Winskill; Nancy Zhang; Andreas Woerner; Marc Pfister
Journal:  Pediatr Rheumatol Online J       Date:  2021-03-25       Impact factor: 3.054

6.  Biologic medicine inclusion in 138 national essential medicines lists.

Authors:  Raphaël Kraus; Rae S M Yeung; Nav Persaud
Journal:  Pediatr Rheumatol Online J       Date:  2021-09-06       Impact factor: 3.054
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.